Published Date: March, 2018
A recent report published by Infinium Global Research on lung cancer therapeutics market provides in depth analysis of segments and sub-segments in global as well as regional lung cancer therapeutics market. The study also highlights the impact of drivers, restraints and macro indicators on the global and regional lung cancer therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global lung cancer therapeutics market. According to report the global lung cancer therapeutics market is projected to grow at a CAGR of 12.50% over the forecast period of 2018-2024.
The report on global lung cancer therapeutics market covers segments such as, type of molecule and disease type. On the basis of type of molecule the global lung cancer therapeutics market is categorized into small molecules and biologics. On the basis of disease type the global lung cancer therapeutics market is categorized into NSCLC and SCLC.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section the key trends and market size for each geography is provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience a growth at a CAGR of x.x% over the period of 2018-2024.
The report provides profiles of the companies in the global lung cancer therapeutics market such as, Astellas Pharma, Pfizer, Amgen, Celgene, AstraZeneca, F. Hofmann-La Roche, GlaxoSmithKline, Aetna, Agennix, Eli Lilly and Boston Biomedical.
The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the global lung cancer therapeutics market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of lung cancer therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the lung cancer therapeutics market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. This report will help manufacturers, suppliers and distributors of the lung cancer therapeutics market to understand the present and future trends in this market and formulate their strategies accordingly.
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Global Lung Cancer Therapeutics Market Overview
3.2. Market Dynamics
3.3. Porter's Five Forces Analysis
3.4. IGR-Growth Matrix Analysis
3.5. Competitive Landscape in the Global Lung Cancer Therapeutics Market
4. Global Lung Cancer Therapeutics Market by Type of Molecule
4.1. Small Molecules
5. Global Lung Cancer Therapeutics Market by Disease Type
6. Global Lung Cancer Therapeutics Market by Region 2018-2024
6.1. North America
7. Company Covered
7.1. Astellas Pharma
7.6. F. Hofmann-la Roche
7.8. Aetna, Agennix
7.9. Eli Lilly
7.10. Boston Biomedical
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter